nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

09.03.2024 | Review

B-Cell Receptor Repertoire: Recent Advances in Autoimmune Diseases

verfasst von: Qian Wang, Delong Feng, Sujie Jia, Qianjin Lu, Ming Zhao

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

In the field of contemporary medicine, autoimmune diseases (AIDs) are a prevalent and debilitating group of illnesses. However, they present extensive and profound challenges in terms of etiology, pathogenesis, and treatment. A major reason for this is the elusive pathophysiological mechanisms driving disease onset. Increasing evidence suggests the indispensable role of B cells in the pathogenesis of autoimmune diseases. Interestingly, B-cell receptor (BCR) repertoires in autoimmune diseases display a distinct skewing that can provide insights into disease pathogenesis. Over the past few years, advances in high-throughput sequencing have provided powerful tools for analyzing B-cell repertoire to understand the mechanisms during the period of B-cell immune response. In this paper, we have provided an overview of the mechanisms and analytical methods for generating BCR repertoire diversity and summarize the latest research progress on BCR repertoire in autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), primary Sjögren’s syndrome (pSS), multiple sclerosis (MS), and type 1 diabetes (T1D). Overall, B-cell repertoire analysis is a potent tool to understand the involvement of B cells in autoimmune diseases, facilitating the creation of innovative therapeutic strategies targeting specific B-cell clones or subsets.

Hayter SM, Cook MC (2012) Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev 11(10):754–765. https://doi.org/10.1016/j.autrev.2012.02.001CrossRefPubMed

Mitratza M, Klijs B, Hak AE, Kardaun JWPF, Kunst AE (2021) Systemic autoimmune disease as a cause of death: mortality burden and comorbidities. Rheumatology (Oxford) 60(3):1321–1330. https://doi.org/10.1093/rheumatology/keaa537CrossRefPubMed

Carter EE, Barr SG, Clarke AE (2016) The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 12(10):605–620. https://doi.org/10.1038/nrrheum.2016.137CrossRefPubMed

Rubin SJS, Bloom MS, Robinson WH (2019) B cell checkpoints in autoimmune rheumatic diseases. Nat Rev Rheumatol 15(5):303–315. https://doi.org/10.1038/s41584-019-0211-0CrossRefPubMed

Zheng B, Yang Y, Chen L, Wu M, Zhou S (2022) B-cell receptor repertoire sequencing: deeper digging into the mechanisms and clinical aspects of immune-mediated diseases. iScience 25(10):105002. https://doi.org/10.1016/j.isci.2022.105002CrossRefPubMedPubMedCentral

Jabbour E et al (2023) The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol 16(1):22. https://doi.org/10.1186/s13045-023-01409-5CrossRefPubMedPubMedCentral

Bashford-Rogers RJM et al (2019) Analysis of the B cell receptor repertoire in six immune-mediated diseases. Nature 574(7776):122–126. https://doi.org/10.1038/s41586-019-1595-3CrossRefPubMedPubMedCentral

Tipton CM et al (2015) Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat Immunol 16(7):755–765. https://doi.org/10.1038/ni.3175CrossRefPubMedPubMedCentral

Early P, Huang H, Davis M, Calame K, Hood L (1980) An immunoglobulin heavy chain variable region gene is generated from three segments of DNA: VH, D and JH. Cell 19(4):981–992. https://doi.org/10.1016/0092-8674(80)90089-6CrossRefPubMed

10.

Weigert M, Gatmaitan L, Loh E, Schilling J, Hood L (1978) Rearrangement of genetic information may produce immunoglobulin diversity. Nature 276(5690):785–790. https://doi.org/10.1038/276785a0CrossRefPubMed

11.

Collins AM, Watson CT (2018) Immunoglobulin light chain gene rearrangements, receptor editing and the development of a self-tolerant antibody repertoire. Front Immunol 9:2249. https://doi.org/10.3389/fimmu.2018.02249CrossRefPubMedPubMedCentral

12.

Jung D, Giallourakis C, Mostoslavsky R, Alt FW (2006) Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu Rev Immunol 24:541–570. https://doi.org/10.1146/annurev.immunol.23.021704.115830CrossRefPubMed

13.

Ji Y, Resch W, Corbett E, Yamane A, Casellas R, Schatz DG (2010) The in vivo pattern of binding of RAG1 and RAG2 to antigen receptor loci. Cell 141(3):419–431. https://doi.org/10.1016/j.cell.2010.03.010CrossRefPubMedPubMedCentral

14.

Foote J, Winter G (1992) Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 224(2):487–499. https://doi.org/10.1016/0022-2836(92)91010-mCrossRefPubMed

15.

Stewart AK, Schwartz RS (1994) Immunoglobulin V regions and the B cell. Blood 83(7):1717–1730CrossRefPubMed

16.

Di Noia JM, Neuberger MS (2007) Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 76:1–22. https://doi.org/10.1146/annurev.biochem.76.061705.090740CrossRefPubMed

17.

Wilson PC et al (1998) Somatic hypermutation introduces insertions and deletions into immunoglobulin V genes. J Exp Med 187(1):59–70. https://doi.org/10.1084/jem.187.1.59CrossRefPubMedPubMedCentral

18.

Cyster JG, Allen CDC (2019) B cell responses: cell interaction dynamics and decisions. Cell 177(3):524–540. https://doi.org/10.1016/j.cell.2019.03.016CrossRefPubMedPubMedCentral

19.

Boyd SD et al (2009) Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci Transl Med 1(12):12ra23. https://doi.org/10.1126/scitranslmed.3000540CrossRefPubMedPubMedCentral

20.

Klein U, Küppers R, Rajewsky K (1997) Evidence for a large compartment of IgM-expressing memory B cells in humans. Blood 89(4):1288–1298CrossRefPubMed

21.

Lin SG, Ba Z, Du Z, Zhang Y, Hu J, Alt FW (2016) Highly sensitive and unbiased approach for elucidating antibody repertoires. Proc Natl Acad Sci USA 113(28):7846–7851. https://doi.org/10.1073/pnas.1608649113CrossRefPubMedPubMedCentral

22.

Mamanova L et al (2010) Target-enrichment strategies for next-generation sequencing. Nat Methods 7(2):111–118. https://doi.org/10.1038/nmeth.1419CrossRefPubMed

23.

Bashford-Rogers RJM et al (2014) Capturing needles in haystacks: a comparison of B-cell receptor sequencing methods. BMC Immunol 15:29. https://doi.org/10.1186/s12865-014-0029-0CrossRefPubMedPubMedCentral

24.

Yeku O, Frohman MA (2011) Rapid amplification of cDNA ends (RACE). Methods Mol Biol 703:107–122. https://doi.org/10.1007/978-1-59745-248-9_8CrossRefPubMed

25.

Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B (2011) Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA 108(23):9530–9535. https://doi.org/10.1073/pnas.1105422108CrossRefPubMedPubMedCentral

26.

He L et al (2014) Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcoding. Sci Rep 4:6778. https://doi.org/10.1038/srep06778CrossRefPubMedPubMedCentral

27.

Streets AM et al (2014) Microfluidic single-cell whole-transcriptome sequencing. Proc Natl Acad Sci USA 111(19):7048–7053. https://doi.org/10.1073/pnas.1402030111CrossRefPubMedPubMedCentral

28.

Zheng GXY et al (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun 8:14049. https://doi.org/10.1038/ncomms14049CrossRefPubMedPubMedCentral

29.

Goldstein LD et al (2019) Massively parallel single-cell B-cell receptor sequencing enables rapid discovery of diverse antigen-reactive antibodies. Commun Biol 2:304. https://doi.org/10.1038/s42003-019-0551-yCrossRefPubMedPubMedCentral

30.

Nemazee D (2017) Mechanisms of central tolerance for B cells. Nat Rev Immunol 17(5):281–294. https://doi.org/10.1038/nri.2017.19CrossRefPubMedPubMedCentral

31.

Getahun A (2022) Role of inhibitory signaling in peripheral B cell tolerance. Immunol Rev 307(1):27–42. https://doi.org/10.1111/imr.13070CrossRefPubMedPubMedCentral

32.

Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC (2003) Predominant autoantibody production by early human B cell precursors. Science 301(5638):1374–1377. https://doi.org/10.1126/science.1086907CrossRefPubMed

33.

Kinnunen T et al (2013) Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest 123(6):2737–2741. https://doi.org/10.1172/JCI68775CrossRefPubMedPubMedCentral

34.

Lamoureux JL, Watson LC, Cherrier M, Skog P, Nemazee D, Feeney AJ (2007) Reduced receptor editing in lupus-prone MRL/lpr mice. J Exp Med 204(12):2853–2864. https://doi.org/10.1084/jem.20071268CrossRefPubMedPubMedCentral

35.

Liu Y et al (2007) Lupus susceptibility genes may breach tolerance to DNA by impairing receptor editing of nuclear antigen-reactive B cells. J Immunol 179(2):1340–1352. https://doi.org/10.4049/jimmunol.179.2.1340CrossRefPubMed

36.

Yurasov S, Hammersen J, Tiller T, Tsuiji M, Wardemann H (2005) B-cell tolerance checkpoints in healthy humans and patients with systemic lupus erythematosus. Ann N Y Acad Sci 1062:165–174. https://doi.org/10.1196/annals.1358.019CrossRefPubMed

37.

Glauzy S et al (2022) Defective early B cell tolerance checkpoints in patients with systemic sclerosis allow the production of self antigen-specific clones. Arthritis Rheumatol 74(2):307–317. https://doi.org/10.1002/art.41927CrossRefPubMed

38.

Meng W et al (2012) B-cell tolerance defects in the B6.Aec1/2 mouse model of Sjögren’s syndrome. J Clin Immunol 32(3):551–564. https://doi.org/10.1007/s10875-012-9663-6CrossRefPubMedPubMedCentral

39.

Glauzy S et al (2017) Defective early B cell tolerance checkpoints in Sjögren’s syndrome patients. Arthritis Rheumatol 69(11):2203–2208. https://doi.org/10.1002/art.40215CrossRefPubMedPubMedCentral

40.

Meffre E (2011) The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases. Ann N Y Acad Sci 1246:1–10. https://doi.org/10.1111/j.1749-6632.2011.06347.xCrossRefPubMedPubMedCentral

41.

Shlomchik MJ, Marshak-Rothstein A, Wolfowicz CB, Rothstein TL, Weigert MG (1987) The role of clonal selection and somatic mutation in autoimmunity. Nature 328(6133):805–811. https://doi.org/10.1038/328805a0CrossRefPubMed

42.

Tiller T et al (2010) Development of self-reactive germinal center B cells and plasma cells in autoimmune Fc gammaRIIB-deficient mice. J Exp Med 207(12):2767–2778. https://doi.org/10.1084/jem.20100171CrossRefPubMedPubMedCentral

43.

Mak A, Tay SH (2014) Environmental factors, toxicants and systemic lupus erythematosus. Int J Mol Sci 15(9):16043–16056. https://doi.org/10.3390/ijms150916043CrossRefPubMedPubMedCentral

44.

Parks CG, de Souza Espindola Santos A, Barbhaiya M, Costenbader KH (2017) Understanding the role of environmental factors in the development of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 31(3):306–320. https://doi.org/10.1016/j.berh.2017.09.005CrossRefPubMedPubMedCentral

45.

Ha E, Bae S-C, Kim K (2022) Recent advances in understanding the genetic basis of systemic lupus erythematosus. Semin Immunopathol 44(1):29–46. https://doi.org/10.1007/s00281-021-00900-wCrossRefPubMed

46.

Zhang Y, Lee T-Y (2022) Revealing the immune heterogeneity between systemic lupus erythematosus and rheumatoid arthritis based on multi-omics data analysis. Int J Mol Sci 23(9):5166. https://doi.org/10.3390/ijms23095166CrossRefPubMedPubMedCentral

47.

Ota M et al (2023) Multimodal repertoire analysis unveils B cell biology in immune-mediated diseases. Ann Rheum Dis 82:1455–1463. https://doi.org/10.1136/ard-2023-224421

48.

Zheng F et al (2021) Immune cell and TCR/BCR repertoire profiling in systemic lupus erythematosus patients by single-cell sequencing. Aging (Albany NY) 13(21):24432–24448. https://doi.org/10.18632/aging.203695CrossRefPubMed

49.

Liu S, Hou XL, Sui WG, Lu QJ, Hu YL, Dai Y (2017) Direct measurement of B-cell receptor repertoire’s composition and variation in systemic lupus erythematosus. Genes Immun 18(1):22–27. https://doi.org/10.1038/gene.2016.45CrossRefPubMed

50.

Odendahl M et al (2000) Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 165(10):5970–5979. https://doi.org/10.4049/jimmunol.165.10.5970CrossRefPubMed

51.

Schickel J-N et al (2017) Self-reactive VH4-34-expressing IgG B cells recognize commensal bacteria. J Exp Med 214(7):1991–2003. https://doi.org/10.1084/jem.20160201CrossRefPubMedPubMedCentral

52.

Pascual V et al (1991) Nucleotide sequence analysis of the V regions of two IgM cold agglutinins. Evidence that the VH4-21 gene segment is responsible for the major cross-reactive idiotype. J Immunol 146(12):4385–4391CrossRefPubMed

53.

Pugh-Bernard AE et al (2001) Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J Clin Invest 108(7):1061–1070. https://doi.org/10.1172/JCI12462CrossRefPubMedPubMedCentral

54.

Yin L et al (2013) IgM repertoire biodiversity is reduced in HIV-1 infection and systemic lupus erythematosus. Front Immunol 4:373. https://doi.org/10.3389/fimmu.2013.00373CrossRefPubMedPubMedCentral

55.

Clarke T et al (2023) Autoantibody repertoire characterization provides insight into the pathogenesis of monogenic and polygenic autoimmune diseases. Front Immunol 14:1106537. https://doi.org/10.3389/fimmu.2023.1106537CrossRefPubMedPubMedCentral

56.

Sakakibara S et al (2017) Clonal evolution and antigen recognition of anti-nuclear antibodies in acute systemic lupus erythematosus. Sci Rep 7(1):16428. https://doi.org/10.1038/s41598-017-16681-yCrossRefPubMedPubMedCentral

57.

Jenks SA, Cashman KS, Woodruff MC, Lee FE-H, Sanz I (2019) Extrafollicular responses in humans and SLE. Immunol Rev 288(1):136–148. https://doi.org/10.1111/imr.12741CrossRefPubMedPubMedCentral

58.

Sankar K, Hoi KH, Hötzel I (2020) Dynamics of heavy chain junctional length biases in antibody repertoires. Commun Biol 3(1):207. https://doi.org/10.1038/s42003-020-0931-3CrossRefPubMedPubMedCentral

59.

Yurasov S et al (2005) Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 201(5):703–711. https://doi.org/10.1084/jem.20042251CrossRefPubMedPubMedCentral

60.

Meffre E, Milili M, Blanco-Betancourt C, Antunes H, Nussenzweig MC, Schiff C (2001) Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J Clin Invest 108(6):879–886. https://doi.org/10.1172/JCI13051CrossRefPubMedPubMedCentral

61.

Wu M et al (2022) Systemic lupus erythematosus patients contain B-cell receptor repertoires sensitive to immunosuppressive drugs. Eur J Immunol 52(4):669–680. https://doi.org/10.1002/eji.202149596CrossRefPubMed

62.

Georgiou G, Ippolito GC, Beausang J, Busse CE, Wardemann H, Quake SR (2014) The promise and challenge of high-throughput sequencing of the antibody repertoire, Nat Biotechnol 32:158–168. https://doi.org/10.1038/nbt.2782

63.

Cappione A et al (2005) Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 115(11):3205–3216. https://doi.org/10.1172/JCI24179CrossRefPubMedPubMedCentral

64.

You X et al (2020) Double negative B cell is associated with renal impairment in systemic lupus erythematosus and acts as a marker for nephritis remission,. Front Med (Lausanne) 7:85. https://doi.org/10.3389/fmed.2020.00085CrossRefPubMed

65.

Moysidou E et al (2023) Increase in double negative B lymphocytes in patients with systemic lupus erythematosus in remission and their correlation with early differentiated T lymphocyte subpopulations. Curr Issues Mol Biol 45(8):6667–6681. https://doi.org/10.3390/cimb45080421CrossRefPubMedPubMedCentral

66.

Sachinidis A, Xanthopoulos K, Garyfallos A (2020) Age-associated B cells (ABCs) in the prognosis, diagnosis and therapy of systemic lupus erythematosus (SLE). Mediterr J Rheumatol 31(3):311–318. https://doi.org/10.31138/mjr.31.3.311CrossRefPubMedPubMedCentral

67.

Jenks SA et al (2018) Distinct effector B cells induced by unregulated Toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity 49(4):725-739.e6. https://doi.org/10.1016/j.immuni.2018.08.015CrossRefPubMedPubMedCentral

68.

Stewart A, Ng JC-F, Wallis G, Tsioligka V, Fraternali F, Dunn-Walters DK (2021) Single-cell transcriptomic analyses define distinct peripheral B cell subsets and discrete development pathways. Front Immunol 12:602539. https://doi.org/10.3389/fimmu.2021.602539CrossRefPubMedPubMedCentral

69.

Maul RW et al (2021) Transcriptome and IgH repertoire analyses show that CD11chi B cells are a distinct population with similarity to B cells arising in autoimmunity and infection. Front Immunol 12:649458. https://doi.org/10.3389/fimmu.2021.649458CrossRefPubMedPubMedCentral

70.

Nickerson KM et al (2023) Age-associated B cells are heterogeneous and dynamic drivers of autoimmunity in mice. J Exp Med 220(5):e20221346. https://doi.org/10.1084/jem.20221346CrossRefPubMedPubMedCentral

71.

Aranburu A et al (2018) Age-associated B cells expanded in autoimmune mice are memory cells sharing H-CDR3-selected repertoires. Eur J Immunol 48(3):509–521. https://doi.org/10.1002/eji.201747127CrossRefPubMed

72.

Russell Knode LM et al (2017) Age-associated B cells express a diverse repertoire of VH and Vκ genes with somatic hypermutation. The Journal of Immunology 198(5):1921–1927. https://doi.org/10.4049/jimmunol.1601106CrossRefPubMed

73.

Urowitz MB et al (2022) Impact of belimumab on organ damage in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 74(11):1822–1828. https://doi.org/10.1002/acr.24901CrossRefPubMed

74.

Shi B et al (2016) Short-term assessment of BCR repertoires of SLE patients after high dose glucocorticoid therapy with high-throughput sequencing. Springerplus 5:75. https://doi.org/10.1186/s40064-016-1709-4CrossRefPubMedPubMedCentral

75.

Huang W et al (2018) Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients. JCI Insight 3(17):e122525. https://doi.org/10.1172/jci.insight.122525CrossRefPubMedPubMedCentral

76.

Meffre E, O’Connor KC (2019) Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. Immunol Rev 292(1):90–101. https://doi.org/10.1111/imr.12821CrossRefPubMedPubMedCentral

77.

Kissel T et al (n.d.) Surface Ig variable domain glycosylation affects autoantigen binding and acts as threshold for human autoreactive B cell activation. Sci Adv 8:eabm1759. https://doi.org/10.1126/sciadv.abm1759

78.

Merino-Vico A, Frazzei G, van Hamburg JP, Tas SW (2023) Targeting B cells and plasma cells in autoimmune diseases: from established treatments to novel therapeutic approaches. Eur J Immunol 53(1):e2149675. https://doi.org/10.1002/eji.202149675CrossRefPubMed

79.

Blazso P, Csomos K, Tipton CM, Ujhazi B, Walter JE (2022) Lineage reconstruction of in vitro identified antigen-specific autoreactive B cells from adaptive immune receptor repertoires. Int J Mol Sci 24(1):225. https://doi.org/10.3390/ijms24010225CrossRefPubMedPubMedCentral

80.

Cowan GJM, Miles K, Capitani L, Giguere SSB, Johnsson H, Goodyear C, McInnes IB, Breusch S, Gray D, Gray M (2020) In Human Autoimmunity, a Substantial Component of the B Cell Repertoire Consists of Polyclonal, Barely Mutated IgG+ve B Cells. Front Immunol 11:395. https://doi.org/10.3389/fimmu.2020.00395

81.

Sabouri Z et al (2014) Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity. Proc Natl Acad Sci USA 111(25):E2567-2575. https://doi.org/10.1073/pnas.1406974111CrossRefPubMedPubMedCentral

82.

Kinslow JD et al (2016) Elevated IgA plasmablast levels in subjects at risk of developing rheumatoid arthritis. Arthritis Rheumatol 68(10):2372–2383. https://doi.org/10.1002/art.39771CrossRefPubMedPubMedCentral

83.

Aterido A, López-Lasanta M, Blanco F et al (2021) Seven chain adaptive immune receptor repertoire analysis in rheumatoid arthritis: association to disease and clinically relevant phenotypes. medRxiv. https://doi.org/10.1101/2021.11.26.21266347

84.

Itoh K et al (2000) Clonal expansion is a characteristic feature of the B-cell repetoire of patients with rheumatoid arthritis. Arthritis Res 2(1):50–58. https://doi.org/10.1186/ar68CrossRefPubMed

85.

Doorenspleet ME et al (2014) Rheumatoid arthritis synovial tissue harbours dominant B-cell and plasma-cell clones associated with autoreactivity. Ann Rheum Dis 73(4):756–762. https://doi.org/10.1136/annrheumdis-2012-202861CrossRefPubMed

86.

Wang Y et al (2019) Rheumatoid arthritis patients display B-cell dysregulation already in the naïve repertoire consistent with defects in B-cell tolerance. Sci Rep 9(1):19995. https://doi.org/10.1038/s41598-019-56279-0CrossRefPubMedPubMedCentral

87.

Wing E et al (2023) Double-negative-2 B cells are the major synovial plasma cell precursor in rheumatoid arthritis. Front Immunol 14:1241474. https://doi.org/10.3389/fimmu.2023.1241474CrossRefPubMedPubMedCentral

88.

Dunlap G et al (2023) Clonal associations of lymphocyte subsets and functional states revealed by single cell antigen receptor profiling of T and B cells in rheumatoid arthritis synovium. bioRxiv, p. 2023.03.18.533282. https://doi.org/10.1101/2023.03.18.533282.

89.

Hu F et al (2018) Impaired CD27+IgD+ B cells with altered gene signature in rheumatoid arthritis. Front Immunol 9:626. https://doi.org/10.3389/fimmu.2018.00626CrossRefPubMedPubMedCentral

90.

Zhang W et al (2022) Dysfunction of CD27+IgD+ B cells correlates with aggravated systemic lupus erythematosus. Clin Rheumatol 41(5):1551–1559. https://doi.org/10.1007/s10067-022-06051-zCrossRefPubMed

91.

Lu DR et al (2018) T cell-dependent affinity maturation and innate immune pathways differentially drive autoreactive B cell responses in rheumatoid arthritis. Arthritis Rheumatol 70(11):1732–1744. https://doi.org/10.1002/art.40578CrossRefPubMedPubMedCentral

92.

Kongpachith S et al (2019) Affinity maturation of the anti-citrullinated protein antibody paratope drives epitope spreading and polyreactivity in rheumatoid arthritis. Arthritis Rheumatol 71(4):507–517. https://doi.org/10.1002/art.40760CrossRefPubMedPubMedCentral

93.

Bos WH, van de Stadt LA, Sohrabian A, Rönnelid J, van Schaardenburg D (2014) Development of anti-citrullinated protein antibody and rheumatoid factor isotypes prior to the onset of rheumatoid arthritis. Arthritis Res Ther 16(2):405. https://doi.org/10.1186/ar4511CrossRefPubMedPubMedCentral

94.

Derksen VFAM, Allaart CF, Van der Helm-Van Mil AHM, Huizinga TWJ, Toes REM, van der Woude D (2022) In rheumatoid arthritis patients, total IgA1 and IgA2 levels are elevated: implications for the mucosal origin hypothesis. Rheumatology (Oxford) 62(1):407–416. https://doi.org/10.1093/rheumatology/keac237CrossRefPubMed

95.

van der Woude D et al (2010) Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 69(8):1554–1561. https://doi.org/10.1136/ard.2009.124537CrossRefPubMed

96.

van de Stadt LA et al (2011) Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum 63(11):3226–3233. https://doi.org/10.1002/art.30537CrossRefPubMed

97.

Sokolove J et al (2012) Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One 7(5):e35296. https://doi.org/10.1371/journal.pone.0035296CrossRefPubMedPubMedCentral

98.

de Moel EC et al (2018) Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes. Arthritis Res Ther 20(1):33. https://doi.org/10.1186/s13075-018-1520-4CrossRefPubMedPubMedCentral

99.

de Moel EC et al (2019) In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. Arthritis Res Ther 21(1):28. https://doi.org/10.1186/s13075-019-1815-0CrossRefPubMedPubMedCentral

100.

Pollastro S et al (2019) Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire. Ann Rheum Dis 78(10):1339–1345. https://doi.org/10.1136/annrheumdis-2018-214898CrossRefPubMed

101.

Gerlag DM et al (2019) Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann Rheum Dis 78(2):179–185. https://doi.org/10.1136/annrheumdis-2017-212763CrossRefPubMed

102.

Mariette X, Criswell LA (2018) Primary Sjögren's syndrome. N Engl J Med 378(10):931–939. https://doi.org/10.1056/NEJMcp1702514

103.

Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM (2010) Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome. J Autoimmun 34(4):400–407. https://doi.org/10.1016/j.jaut.2009.10.004CrossRefPubMed

104.

Theander E et al (2011) Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren’s syndrome. Ann Rheum Dis 70(8):1363–1368. https://doi.org/10.1136/ard.2010.144782CrossRefPubMed

105.

Sène D et al (2018) Ectopic germinal center-like structures in minor salivary gland biopsy tissue predict lymphoma occurrence in patients with primary Sjögren’s syndrome. Arthritis Rheumatol 70(9):1481–1488. https://doi.org/10.1002/art.40528CrossRefPubMed

106.

Nocturne G, Mariette X (2015) Sjögren syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol 168(3):317–327. https://doi.org/10.1111/bjh.13192CrossRefPubMed

107.

Chen YH, Wang XY, Jin X, Yang Z, Xu J (2021) Rituximab therapy for primary Sjögren’s syndrome. Front Pharmacol 12:731122. https://doi.org/10.3389/fphar.2021.731122CrossRefPubMedPubMedCentral

108.

Abdulahad WH, Kroese FGM, Vissink A, Bootsma H (2012) Immune regulation and B-cell depletion therapy in patients with primary Sjögren’s syndrome. J Autoimmun 39(1–2):103–111. https://doi.org/10.1016/j.jaut.2012.01.009CrossRefPubMed

109.

Pijpe J et al (2005) Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren’s syndrome and associated MALT lymphoma. Ann Rheum Dis 64(6):958–960. https://doi.org/10.1136/ard.2004.030684CrossRefPubMed

110.

Visser A et al (2018) Acquisition of N-glycosylation sites in immunoglobulin heavy chain genes during local expansion in parotid salivary glands of primary Sjögren patients. Front Immunol 9:491. https://doi.org/10.3389/fimmu.2018.00491CrossRefPubMedPubMedCentral

111.

Visser A et al (2020) Repertoire analysis of B-cells located in striated ducts of salivary glands of patients with Sjögren’s syndrome. Front Immunol 11:1486. https://doi.org/10.3389/fimmu.2020.01486CrossRefPubMedPubMedCentral

112.

Bende RJ, Aarts WM, Riedl RG, de Jong D, Pals ST, van Noesel CJM (2005) Among B cell non-Hodgkin’s lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 201(8):1229–1241. https://doi.org/10.1084/jem.20050068CrossRefPubMedPubMedCentral

113.

Bende RJ, Janssen J, Wormhoudt TAM, Wagner K, Guikema JEJ, van Noesel CJM (2016) Identification of a novel stereotypic IGHV4-59/IGHJ5-encoded B-cell receptor subset expressed by various B-cell lymphomas with high affinity rheumatoid factor activity. Haematologica 101(5):e200-203. https://doi.org/10.3324/haematol.2015.139626CrossRefPubMedPubMedCentral

114.

Bende RJ et al (2020) Salivary gland mucosa-associated lymphoid tissue-type lymphoma from Sjögren’s syndrome patients in the majority express rheumatoid factors affinity-selected for IgG. Arthritis Rheumatol 72(8):1330–1340. https://doi.org/10.1002/art.41263CrossRefPubMedPubMedCentral

115.

Carlotti E et al (2022) High-throughput sequencing of IgH gene in minor salivary glands from Sjögren’s syndrome patients reveals dynamic B cell recirculation between ectopic lymphoid structures. Clin Exp Rheumatol 40(12):2363–2372. https://doi.org/10.55563/clinexprheumatol/82u3csCrossRefPubMed

116.

Hamza N et al (2012) Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren’s syndrome after B cell depletion therapy. Ann Rheum Dis 71(11):1881–1887. https://doi.org/10.1136/annrheumdis-2011-201189CrossRefPubMed

117.

Gellrich S et al (1999) Analysis of V(H)-D-J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjögren’s syndrome. Arthritis Rheum 42(2):240–247. https://doi.org/10.1002/1529-0131(199902)42:2%3c240::AID-ANR5%3e3.0.CO;2-ICrossRefPubMed

118.

Stott DI, Hiepe F, Hummel M, Steinhauser G, Berek C (1998) Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren’s syndrome. J Clin Invest 102(5):938–946. https://doi.org/10.1172/JCI3234CrossRefPubMedPubMedCentral

119.

Bende RJ et al (2015) Stereotypic rheumatoid factors that are frequently expressed in mucosa-associated lymphoid tissue-type lymphomas are rare in the labial salivary glands of patients with Sjögren’s syndrome. Arthritis Rheumatol 67(4):1074–1083. https://doi.org/10.1002/art.39002CrossRefPubMed

120.

Nocturne G et al (2016) Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren’s syndrome. Arthritis Rheumatol 68(4):977–985. https://doi.org/10.1002/art.39518CrossRefPubMed

121.

Hansen A et al (2005) Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjögren’s syndrome. Arthritis Rheum 52(7):2109–2119. https://doi.org/10.1002/art.21129CrossRefPubMed

122.

Hansen A et al (2002) Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren’s syndrome. Arthritis Rheum 46(8):2160–2171. https://doi.org/10.1002/art.10445CrossRefPubMed

123.

Hamza N et al (2015) Ig gene analysis reveals altered selective pressures on Ig-producing cells in parotid glands of primary Sjögren’s syndrome patients. J Immunol 194(2):514–521. https://doi.org/10.4049/jimmunol.1302644CrossRefPubMed

124.

Correale J, Marrodan M, Ysrraelit MC (2019) Mechanisms of neurodegeneration and axonal dysfunction in progressive multiple sclerosis. Biomedicines 7(1):14. https://doi.org/10.3390/biomedicines7010014CrossRefPubMedPubMedCentral

125.

Arneth B, Kraus J (2022) Laboratory biomarkers of multiple sclerosis (MS). Clin Biochem 99:1–8. https://doi.org/10.1016/j.clinbiochem.2021.10.004CrossRefPubMed

126.

Brändle SM et al (2016) Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc Natl Acad Sci USA 113(28):7864–7869. https://doi.org/10.1073/pnas.1522730113CrossRefPubMedPubMedCentral

127.

Beltrán E et al (2014) Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation. Brain 137(Pt 10):2703–2714. https://doi.org/10.1093/brain/awu205CrossRefPubMed

128.

Thompson AJ et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173. https://doi.org/10.1016/S1474-4422(17)30470-2CrossRefPubMed

129.

Sola P et al (2011) Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM. Mult Scler 17(3):303–311. https://doi.org/10.1177/1352458510386996CrossRefPubMed

130.

Gelfand JM, Cree BAC, Hauser SL (2017) Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics 14(4):835–841. https://doi.org/10.1007/s13311-017-0557-4CrossRefPubMedPubMedCentral

131.

Svenningsson A et al (2022) Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol 21(8):693–703. https://doi.org/10.1016/S1474-4422(22)00209-5CrossRefPubMed

132.

Stern JNH et al (2014) B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci Transl Med 6(248):248ra107. https://doi.org/10.1126/scitranslmed.3008879CrossRefPubMedPubMedCentral

133.

Palanichamy A et al (2014) Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Sci Transl Med 6(248):248ra106. https://doi.org/10.1126/scitranslmed.3008930CrossRefPubMedPubMedCentral

134.

Johansen JN et al (2015) Intrathecal BCR transcriptome in multiple sclerosis versus other neuroinflammation: equally diverse and compartmentalized, but more mutated, biased and overlapping with the proteome. Clin Immunol 160(2):211–225. https://doi.org/10.1016/j.clim.2015.06.001CrossRefPubMed

135.

Lindeman I et al (2022) Stereotyped B-cell responses are linked to IgG constant region polymorphisms in multiple sclerosis. Eur J Immunol 52(4):550–565. https://doi.org/10.1002/eji.202149576CrossRefPubMed

136.

Eggers EL et al (2017) Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients,. JCI Insight 2(22):e92724. https://doi.org/10.1172/jci.insight.92724CrossRefPubMedPubMedCentral

137.

Tomescu-Baciu A et al (2019) Persistence of intrathecal oligoclonal B cells and IgG in multiple sclerosis. J Neuroimmunol 333:576966. https://doi.org/10.1016/j.jneuroim.2019.576966CrossRefPubMed

138.

Bankoti J et al (2014) In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses. Ann Neurol 75(2):266–276. https://doi.org/10.1002/ana.24088CrossRefPubMedPubMedCentral

139.

Greenfield AL et al (2019) Longitudinally persistent cerebrospinal fluid B cells can resist treatment in multiple sclerosis. JCI Insight 4(6):e126599. https://doi.org/10.1172/jci.insight.126599CrossRefPubMedPubMedCentral

140.

Lovato L et al (2011) Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain 134(Pt 2):534–541. https://doi.org/10.1093/brain/awq350CrossRefPubMedPubMedCentral

141.

Lehmann-Horn K, Wang S-Z, Sagan SA, Zamvil SS, von Büdingen H-C (2016) B cell repertoire expansion occurs in meningeal ectopic lymphoid tissue. JCI Insight 1(20):e87234. https://doi.org/10.1172/jci.insight.87234CrossRefPubMedPubMedCentral

142.

Qin Y, Duquette P, Zhang Y, Talbot P, Poole R, Antel J (1998) Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 102(5):1045–1050. https://doi.org/10.1172/JCI3568CrossRefPubMedPubMedCentral

143.

von Büdingen HC, Kuo TC, Sirota M, van Belle CJ, Apeltsin L, Glanville J, Cree BA, Gourraud PA, Schwartzburg A, Huerta G, Telman D, Sundar PD, Casey T, Cox DR, Hauser SL (2012) B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest 122(12):4533–43. https://doi.org/10.1172/JCI63842

144.

Zheng Y et al (2020) IgG index revisited: diagnostic utility and prognostic value in multiple sclerosis. Front Immunol 11:1799. https://doi.org/10.3389/fimmu.2020.01799CrossRefPubMedPubMedCentral

145.

Gasperi C et al (2019) Association of intrathecal immunoglobulin G synthesis with disability worsening in multiple sclerosis. JAMA Neurol 76(7):841–849. https://doi.org/10.1001/jamaneurol.2019.0905CrossRefPubMedPubMedCentral

146.

Obermeier B et al (2008) Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med 14(6):688–693. https://doi.org/10.1038/nm1714CrossRefPubMed

147.

Laurent SA et al (2023) Effect of ocrelizumab on B- and T-cell receptor repertoire diversity in patients with relapsing multiple sclerosis from the randomized phase III OPERA trial. Neurol Neuroimmunol Neuroinflamm 10(4):e200118. https://doi.org/10.1212/NXI.0000000000200118CrossRefPubMedPubMedCentral

148.

Kowarik MC et al (2021) Differential effects of fingolimod and natalizumab on B cell repertoires in multiple sclerosis patients. Neurotherapeutics 18(1):364–377. https://doi.org/10.1007/s13311-020-00975-7CrossRefPubMed

149.

Ruschil C et al (2023) Cladribine treatment specifically affects peripheral blood memory B cell clones and clonal expansion in multiple sclerosis patients. Front Immunol 14:1133967. https://doi.org/10.3389/fimmu.2023.1133967CrossRefPubMedPubMedCentral

150.

Teschner VE et al (2023) Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment response. Ther Adv Neurol Disord 16:17562864231211076. https://doi.org/10.1177/17562864231211077CrossRefPubMedPubMedCentral

151.

Hinman RM, Cambier JC (2014) Role of B lymphocytes in the pathogenesis of type 1 diabetes. Curr Diab Rep 14(11):543. https://doi.org/10.1007/s11892-014-0543-8CrossRefPubMed

152.

Vandamme C, Kinnunen T (2020) B cell helper T cells and type 1 diabetes. Scand J Immunol 92(4):e12943. https://doi.org/10.1111/sji.12943CrossRefPubMedPubMedCentral

153.

Smith MJ et al (2015) Loss of anergic B cells in prediabetic and new-onset type 1 diabetic patients. Diabetes 64(5):1703–1712. https://doi.org/10.2337/db13-1798CrossRefPubMed

154.

Kozhakhmetova A et al (2018) A quarter of patients with type 1 diabetes have co-existing non-islet autoimmunity: the findings of a UK population-based family study. Clin Exp Immunol 192(3):251–258. https://doi.org/10.1111/cei.13115CrossRefPubMedPubMedCentral

155.

Triolo TM et al (2011) Additional autoimmune disease found in 33% of patients at type 1 diabetes onset. Diabetes Care 34(5):1211–1213. https://doi.org/10.2337/dc10-1756CrossRefPubMedPubMedCentral

156.

Catani M, Walther D, Christie MR, McLaughlin KA, Bonifacio E, Eugster A (2016) Isolation of human monoclonal autoantibodies derived from pancreatic lymph node and peripheral blood B cells of islet autoantibody-positive patients. Diabetologia 59(2):294–298. https://doi.org/10.1007/s00125-015-3792-4CrossRefPubMed

157.

Seay HR, Yusko E, Rothweiler SJ, Zhang L, Posgai AL, Campbell-Thompson M, Vignali M, Emerson RO, Kaddis JS, Ko D, Nakayama M, Smith MJ, Cambier JC, Pugliese A, Atkinson MA, Robins HS, Brusko TM (2016) Tissue distribution and clonal diversity of the T and B cell repertoire in type 1 diabetes. JCI Insight 1(20):e88242. https://doi.org/10.1172/jci.insight.88242

158.

Ahmed R et al (2019) A public BCR present in a unique dual-receptor-expressing lymphocyte from type 1 diabetes patients encodes a potent T cell autoantigen. Cell 177(6):1583-1599.e16. https://doi.org/10.1016/j.cell.2019.05.007CrossRefPubMedPubMedCentral

159.

Japp AS et al (2021) TCR+/BCR+ dual-expressing cells and their associated public BCR clonotype are not enriched in type 1 diabetes. Cell 184(3):827-839.e14. https://doi.org/10.1016/j.cell.2020.11.035CrossRefPubMedPubMedCentral

160.

Ahmed R, Omidian Z, Giwa A, Donner T, Jie C, Hamad ARA (2021) A reply to ‘TCR+/BCR+ dual-expressing cells and their associated public BCR clonotype are not enriched in type 1 diabetes.’ Cell 184(3):840–843. https://doi.org/10.1016/j.cell.2020.11.036CrossRefPubMedPubMedCentral

161.

Ganusov VV, De Boer RJ (2007) Do most lymphocytes in humans really reside in the gut? Trends Immunol 28(12):514–518. https://doi.org/10.1016/j.it.2007.08.009CrossRefPubMed

162.

Fraser NLW, Rowley G, Field M, Stott DI (2003) The VH gene repertoire of splenic B cells and somatic hypermutation in systemic lupus erythematosus. Arthritis Res Ther 5(2):R114-121. https://doi.org/10.1186/ar627CrossRefPubMedPubMedCentral

163.

Trück J et al (2021) Biological controls for standardization and interpretation of adaptive immune receptor repertoire profiling. Elife 10:e66274. https://doi.org/10.7554/eLife.66274CrossRefPubMedPubMedCentral

164.

Vistain LF, Tay S (2021) Single-cell proteomics. Trends Biochem Sci 46(8):661–672. https://doi.org/10.1016/j.tibs.2021.01.013CrossRefPubMed

165.

Chambers DC, Carew AM, Lukowski SW, Powell JE (2019) Transcriptomics and single-cell RNA-sequencing. Respirology 24(1):29–36. https://doi.org/10.1111/resp.13412CrossRefPubMed

166.

Baek S, Lee I (2020) Single-cell ATAC sequencing analysis: from data preprocessing to hypothesis generation. Comput Struct Biotechnol J 18:1429–1439. https://doi.org/10.1016/j.csbj.2020.06.012CrossRefPubMedPubMedCentral

167.

Vickovic S et al (2022) Three-dimensional spatial transcriptomics uncovers cell type localizations in the human rheumatoid arthritis synovium. Commun Biol 5(1):129. https://doi.org/10.1038/s42003-022-03050-3CrossRefPubMedPubMedCentral

168.

Hardt U et al (2022) Integrated single cell and spatial transcriptomics reveal autoreactive differentiated B cells in joints of early rheumatoid arthritis. Sci Rep 12(1):11876. https://doi.org/10.1038/s41598-022-15293-5

169.

Gao A et al (2022) Tissue-resident memory T cells: the key frontier in local synovitis memory of rheumatoid arthritis. J Autoimmun 133:102950. https://doi.org/10.1016/j.jaut.2022.102950CrossRefPubMed

Titel: B-Cell Receptor Repertoire: Recent Advances in Autoimmune Diseases
verfasst von: Qian Wang
Delong Feng
Sujie Jia
Qianjin Lu
Ming Zhao
Publikationsdatum: 09.03.2024
Verlag: Springer US
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 1/2024
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-024-08984-6

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

B-Cell Receptor Repertoire: Recent Advances in Autoimmune Diseases

Abstract

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Is Food-Triggered Atopic Dermatitis a Form of Systemic Contact Dermatitis?

Advancing Understanding of Childhood Asthma: Lessons Learned from Birth Cohort Studies

Clinical Presentation and Diagnosis of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review

Markers of Endothelial Dysfunction in Kawasaki Disease: An Update

Cellular and Molecular Mechanisms of Mast Cells in Atherosclerotic Plaque Progression and Destabilization

A Global View of Pemphigus: Geographical Variations

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO